Objective Predictors of the need to initiate noninvasive ventilation (NIV) in stable COPD outpatients with acute exacerbation of chronic obstructive pulmonary disease (COPD-AE) are insufficiently defined. The objective of this study was to investigate predictors of the need to initiate NIV in stable COPD-AE outpatients. Methods A total of 140 consecutive stable COPD outpatients who were hospitalized for COPD-AE for the first time were retrospectively examined. Demographic and clinical parameters measured in the stable state were evaluated, including data for arterial blood gases, the pulmonary function, body mass index and dyspnea scores. Results Of the 140 patients included, NIV was used in 32 (23%) patients. In a univariate Cox proportional hazards analysis, the baseline partial pressure of arterial carbon dioxide (PaCO2) (hazard ratio (HR), 1.14 per mmHg; 95% confidence interval (CI), 1.08-1.21) and forced expiratory volume in one second (FEV1)% predicted (HR, 1.03 per %; 95% CI, 1.01-1.05) were identified to be significant predictors. A multivariate logistic regression analysis showed only the PaCO2 (HR, 1.18 per mmHg; 95% CI, 1.12-1.26) to be a significant predictor. Conclusion Our results suggest that the PaCO2 measured in the stable state is an independent significant predictor of the need to initiate NIV in COPD-AE patients who are hospitalized for the first time.
Introduction
Acute exacerbation of chronic obstructive pulmonary disease (COPD-AE) is a major cause of hospital admission and is associated with increased mortality, an impaired quality of life and higher health care expenditures (1) (2) (3) . Randomized controlled trials have shown that noninvasive ventilation (NIV) reduces the need for endotracheal intubation, reduces complications and increases short-term survival in patients with COPD-AE (4, 5) . Therefore, NIV is currently widely used as a first line treatment in patients with severe COPD-AE. The clinical features demonstrated to have an association with the development of COPD-AE include a history of prior COPD-AE, hypercapnia, a lower forced expiratory volume in one second (FEV1) % predicted, the BODE (body mass index (BMI), airflow obstruction, dyspnea and exercise capacity) index, an impaired health status, hypoxemia, pulmonary hypertension and comorbidities (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Although clinical predictors of the development of COPD-AE have been investigated in a number of previous studies, those affecting the need to initiate NIV in stable COPD outpatients who develop COPD-AE have not been sufficiently studied. Identifying factors that can be used to predict the need for NIV support to treat COPD-AE would be of great benefit to clinicians, as detecting patients at high risk in the early stage is important, and such predictors would be helpful in monitoring patients and making therapeutic decisions.
We conducted this study to explore predictors of the need to initiate NIV in stable COPD outpatients who develop COPD-AE.
Materials and Methods

Patient selection
This study was approved by the Ethics Committee of Tosei General Hospital (Aichi, Japan). The records of consecutive COPD patients who had received outpatient care and were admitted for the first time with COPD-AE to Tosei General Hospital between July 1996 and October 2001 were retrospectively collected and analyzed. For each patient, the first admission with COPD-AE during this time period was taken to be the index admission. The diagnosis of COPD was established based on the global initiative for chronic obstructive lung disease (GOLD) consensus statement as the ratio of the forced expiratory volume in one second over a forced vital capacity (FEV1/FVC) of less than 0.7 following bronchodilator inhalation performed in the stable phase prior to admission (18) . COPD-AE was defined as a change in the patient's symptoms beyond daily variations requiring an adjustment of regular medications (19) . Patients with a secondary diagnosis of congestive heart failure, chronic respiratory conditions other than COPD or lung cancer and those with obvious pneumonia on a chest roentgenogram were excluded. In order to assess the data of the outpatients (in the stable state), we excluded patients with missing stable state data for the 6-month period before the date of the first admission for COPD-AE. All of the patients analyzed in this study visited our hospital once a month or every two months.
Data collection
Detailed clinical and laboratory data obtained in a stable state within the 6-month period before the date of the first admission for COPD-AE and data obtained on admission were collected from the medical records. These data included age, the smoking status and number of pack-years, BMI, the use of long-term oxygen therapy (LTOT), ambulatory treatment prior to admission, arterial blood gas values, pulmonary function parameters, the GOLD stage and the severity of dyspnea. For each patient, the stable state data evaluated on the day nearest to the admission date were taken as the index data. Current smokers were defined as patients who had smoked within the previous six months. The arterial blood gases were measured with the patient at rest breathing room air. Spirometry (CHESTAC-55V; Chest, Tokyo, Japan) and the diffusing capacity of the lung for carbon monoxide (DLco) (CHESTAC-55V; Chest, Tokyo, Japan) were measured according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) recommendations for physiological assessments (20, 21) . The modified Medical Research Council (mMRC) scale was used to assess the severity of dyspnea (22) . The mMRC score system ranges from 0 to 4 points, with higher scores reflecting a greater degree of dyspnea. All laboratory and clinical data were evaluated every three to six months in all patients.
Indication criteria and NIV settings
The indications for NIV were determined by the attending physicians. The indication criteria for NIV to treat COPD-AE in this study included the presence of at least two of the following three criteria: 1) respiratory distress, as evidenced by moderate-to-severe dyspnea, the use of accessory muscles of respiration or abdominal paradox; 2) acute respiratory failure, as evidenced by a low arterial pH (<7.35) with hypercapnia (>45 mmHg); and 3) a high respiratory rate (>24 breaths/min) (18, 23) . To evaluate the indications for NIV, the attending physicians performed a physical examination of each patient and evaluated the arterial blood gas data obtained on admission. Among patients who did not fulfill the indication criteria for NIV on admission, each patient's respiratory condition and blood gas data were reevaluated within at least 24 hours of admission. COPD-AE frequently leads to progressive severe hypercapnia or worsening of the level of consciousness. In such cases, we initiated NIV treatment at the moment the patient fulfilled the indication criteria for NIV. The contraindications to NIV were as follows: respiratory arrest or the need for immediate intubation, hypotension, uncontrolled arrhythmia, upper airway obstruction or facial trauma, an inability to clear secretions and an inability to cooperate or fit the mask. NIV was administered in the spontaneous/time-triggered (S/T) mode through a nasal or full facial mask using a bi-level positive airway pressure ventilator (BiPAP Vision; Respironics, Inc.). The fraction of inspired oxygen (FiO2) was titrated to target the pulse oximetry oxygen saturation to above 90%. The patients were continuously monitored using an electrocardiogram, pulse oximetry, invasive or noninvasive measurement of blood pressure and an assessment of the respiratory rate. The initial inspiratory positive airway pressure (IPAP) was set at 8 cmH2O, and the level was raised by 2 cmH2O, as tolerated, not to exceed 24 cmH2O. The initial expiratory positive airway pressure (EPAP) was set at 4 cmH2O, and the level was raised by 1-2 cmH2O if needed to improve comfort.
Statistical analysis
All values are shown as the mean ± standard deviation (SD) or number. A p value of less than 0.05 was considered to indicate statistical significance in all analyses. The unpaired t-test and chi-square analyses were used to compare the demographic and physiological characteristics between the groups, and variables with a p value of less than 0.10 were included in univariate Cox proportional hazards and multiple logistic regression analyses to investigate the predictors affecting the initiation of NIV in the patients with COPD-AE. 
Results
Patient selection
During an approximately 5-year period, 159 consecutive COPD patients who had received outpatient care at our hospital were admitted for the first time with a diagnosis of COPD-AE. Among these patients, 19 were excluded for having an incomplete minimum data set for the stable state before the first admission. The remaining 140 patients comprised the study cohort. On admission, no patients satisfied the contraindication criteria for NIV and no patients were intubated.
Demographic and clinical characteristics
The demographic and clinical characteristics of all patients in the stable state and on admission are summarized in Tables 1 and 2 . The mean age was 73.7 years (SD: 8.0 years). The patients were predominantly men (84%) and current or former smokers (97.9%). On average, the patients had moderate airway obstruction with a mean FEV1 of 47.9±19.8% predicted, while 85 patients (61%) were classified as having GOLD stage III or IV disease. The pH level during the clinically stable phase was within the normal range in all patients (arterial pH ! 7.35). Of the study participants, 87 (62.1%) already had received ambulatory treatment for COPD prior to the first admission for COPD-AE and 18 (12.9%) were receiving LTOT. The number of patients who had been treated with ambulatory therapies other than LTOT were as follows: long-acting anticholinergics, 68: longacting β-agonists, 46: theophylline, 27: inhaled glucocorticoids, 20 and oral glucocorticoids, 3. Following admission for COPD-AE, a total of 32 (22.9%) patients received NIV. Of these 32 patients, there were 19 patients with moderateto-severe acidosis (arterial pH <7.35), 27 patients in a hypercapnic state (PaCO2 >45 mmHg) and 17 patients in both a hypercapnic and acidotic state (PaCO2 >45 mmHg, arterial pH <7.35). The GOLD stages of the patients who received NIV were as follows: I, 2, II, 6, III, 13 and IV, 11. The treatment regimens for the patients who did not receive NIV included controlled oxygen therapy administered via a nasal cannula or venturi mask as needed in order to achieve a level of arterial oxygen saturation of 90%. Consequently, 68 patients (63.0%) received controlled oxygen therapy. The treatments prescribed for COPD-AE were as follows: shortacting β-agonists, 97.2%: antibiotics, 82.4% and systemic corticosteroids, 36.1%. In contrast, the treatments prescribed for the patients who received NIV were as follows: shortacting β-agonists, 93.8%: antibiotics, 100.0% and systemic corticosteroids, 31.3%.
Analysis of the predictors of the need to introduce NIV to treat COPD-AE
The differences in patient characteristics and laboratory data obtained in a stable state between the patients treated with and without NIV are shown in Table 3 . On average, the patients treated with NIV had a lower FEV1% predicted (p=0.02) and a higher PaCO2 (p<0.001). Predictors of the need to initiate NIV in all 140 patients were evaluated using a univariate Cox proportional hazards analysis, the results of which are shown in Table 4 . A high PaCO2 (p<0.001) and a low FEV1% predicted (p=0.004) were shown to be predictors of the need to initiate NIV in a univariate analysis. However, in a multivariate logistic regression analysis, a high PaCO2 was identified to be the sole independent predictor affecting the initiation of NIV (Table 5 ).
Discussion
In this study, we assessed predictors affecting the need to initiate NIV on the first admission for COPD-AE in stable COPD outpatients. Determining the predictors of the need for NIV support in patients with COPD-AE is important for several reasons, including identifying factors that could lead to specific treatments and detecting patients in whom more powerful therapeutic interventions should be performed. The major finding of our study is that the PaCO2 measured in a stable state was identified to be the sole independent predictor affecting the need to initiate NIV in the COPD-AE patients. The second important point is that markers of airflow obstruction, e.g. FEV1, hypoxemia and dyspnea, were not retained as independent predictors in the multivariate logistic regression analysis, although these factors are well-known clinical features associated with the development of COPD-AE.
We examined the differences in patient characteristics and laboratory data obtained in the stable state and found that the PaCO2 and FEV1% predicted were statistically significantly different between the patients treated with and without NIV. Additionally, according to a univariate analysis, we detected two statistically significant predictors of the need to initiate NIV: PaCO2 and FEV1% predicted. It is reasonable that both the PaCO2 and FEV1% predicted, which are established prognostic factors in patients with COPD, are also predictors of the need to initiate NIV during exacerbation, given that the need for NIV support implies the development of severe respiratory failure associated with a poor prognosis (1, (24) (25) (26) (27) (28) (29) . However, it is noteworthy that, in the multivariate logistic regression analysis, the severity of airway obstruction assessed according to the FEV1% predicted was no longer identified as a predictor. Only the PaCO2 remained a significant predictor, despite the fact that deterioration of the pulmonary function results in retention of the PaCO2.
The significance of the PaCO2 in COPD patients has been evaluated in a number of previous studies. Consequently, the PaCO2 is regarded to be a poor prognostic indicator in general and has been demonstrated to be associated with the development of COPD-AE (1, 7, (24) (25) (26) (27) (28) (29) (30) . However, the majority of studies have focused on severely hypoxemic patients requiring NIV or patients who had previously experienced COPD-AE. The significance of monitoring of the PaCO2 measured in the stable state in mild to moderate COPD patients with no previous history of COPD-AE has not been extensively studied. In particular, to our knowledge, no previous studies have examined the ability of the PaCO2 measured during a clinically stable period to predict the future need to initiate NIV in COPD-AE outpatients with a wide range of disease severity.
In view of our results, the presence of hypercapnia in a stable state, which is suggestive of chronic alveolar hypoventilation, may be used to more accurately identify patients who will develop severe respiratory failure than the FEV1% predicted. The FEV1 is limited in that it measures only one aspect of COPD and is not predictive of disease progression, especially in the early stage of COPD (31, 32) . Therefore, monitoring the PaCO2 as well as the pulmonary function in COPD outpatients, including those with mild severity, is important. Additionally, COPD outpatients with a higher PaCO2, irrespective of a fully compensated status (normal pH), may be prone to decompensation of their respiratory condition compared with normocapnic patients, given that our study cohort was comprised of only patients without acidosis during the clinically stable phase.
Some limitations of this study should be mentioned. First, this study was a single-center, retrospective study. Second, we were unable to entirely eliminate the potential contributions of some of the excluded but important variables. The sample size may have been too small to detect other potentially important predictors. Therefore, the difference between the FEV1% predicted and the PaCO2 in terms of predicting the initiation of NIV may be attributable to the sample size. However, we believe that the sample size of 140 patients allowed for reliable analyses, and the distribution of the FEV1% predicted in our patients was quite large (47.9± 19.8%) and comparable to that reported in previous studies. For example, in a recent longitudinal observational study of a large COPD cohort, the mean FEV1% predicted was 48± 16% (6) . Therefore, we think that the variability in the FEV1% predicted observed in our study was high enough to ensure the predictive value. Third, some important factors previously demonstrated to be predictors of the development of COPD-AE were not assessed in our study, e.g. indices of the quality of life, exercise capacity and pulmonary hypertension (7-15). We did not systematically evaluate BNP data or detailed ultrasound cardiography data obtained within the study period for all stable COPD outpatients. Therefore, we cannot provide detailed data regarding pulmonary hypertension associated with COPD. Furthermore, important prognostic factors, such as the modified MRC, evaluated in this study were not retained in the final multivariate model. In future studies, exploring predictors, including these factors, is warranted. Fourth, the rate of systemic corticosteroid use in the patients with COPD-AE was comparatively low in this study. This may have been due to the fairly high average age of the patients (73.7±8.0 years) who were admitted with COPD-AE during the study period. Consequently, the attending physicians may have refrained from using systemic corticosteroids for fear of potential side effects.
In conclusion, our results suggest that a high PaCO2 measured during the clinically stable period is an independent predictor of the need to initiate NIV during the first admission for COPD-AE. The presence of hypercapnia at baseline may help to identify patients who will experience decompensation of their respiratory condition and develop severe acute respiratory failure.
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